Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company
Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited (“Cellnovo”), the wholly-owned subsidiary company of Cellnovo Group SA, a Med Tech company marketing the first mobile, connected, all-in-one diabetes management system, listed on Euronext Paris. This is a follow on facility by Kreos subsequent to its €7 million growth capital facility in 2015 and its €5 million growth capital facility in 2017.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Dafni Loizou (Associate) from our Corporate Team, and Paul Kay (Partner) from our Banking Team. Foreign counsel who have advised on this transaction are Reinhart Marville Torre (French law).
News & Insights
Charles Russell Speechlys advises on sale of dental practice Feltham Dental
Feltham Dental was established in 1982, the business is an integral part of the community and has many generations of loyal patients.
Working abroad: unintended consequences
Discovering the implications of working abroad in relation to employment, tax, financial regulations and immigration,